Management Strategies for Tirzeptide-Induced Hyperlipidemia

Assessment and Initial Management

The American College of Cardiology recommends evaluating for secondary causes of hyperlipidemia, including obesity, metabolic syndrome, diabetes, liver/kidney disease, hypothyroidism, and other medications that may increase triglycerides 1, 2
The American College of Cardiology defines moderate hypertriglyceridemia as triglycerides 175-499 mg/dL (2.0-5.6 mmol/L) 3
The American College of Cardiology defines severe hypertriglyceridemia as triglycerides ≥500 mg/dL (≥5.6 mmol/L) 4
The American Academy of Family Physicians defines very severe hypertriglyceridemia as triglycerides ≥1,000 mg/dL (≥11.3 mmol/L) 5
Lifestyle modifications, including weight loss if overweight/obese, increased physical activity, smoking cessation, and reduced alcohol consumption, are recommended as first-line treatment 6, 7, 1

For patients with moderate hypertriglyceridemia (175-499 mg/dL), the American College of Cardiology recommends addressing lifestyle factors and secondary causes first, and considering statin therapy if triglycerides remain elevated after addressing lifestyle factors 1, 8, 3
For patients with severe hypertriglyceridemia (≥500 mg/dL), the American College of Cardiology recommends implementing a very low-fat diet, avoiding refined carbohydrates and alcohol, and considering omega-3 fatty acid supplementation 7, 1, 4
Fibrates are recommended as first-line pharmacological treatment for patients at risk of pancreatitis, especially with triglycerides ≥1,000 mg/dL 2, 6

The American Academy of Family Physicians recommends fibrates as first-line treatment for severe hypertriglyceridemia and pancreatitis risk 2, 6
Statins are effective for moderate hypertriglyceridemia and cardiovascular risk reduction, but should not be used alone for severe hypertriglyceridemia 1, 2, 5
Combination therapy with statins and fibrates increases the risk of myositis 7, 8

The American Diabetes Association recommends prioritizing glycemic control as the first step in managing hypertriglyceridemia in patients with diabetes 7, 8
Most lipid-lowering medications should be avoided during pregnancy 8

Failing to address underlying causes before initiating pharmacotherapy can lead to ineffective treatment 1, 2
Using statins alone for severe hypertriglyceridemia (≥500 mg/dL) can increase the risk of pancreatitis 2, 5
Overlooking the increased risk of myositis with statin-fibrate combinations can lead to adverse events 7, 8